Sanofi Aktie

79,64 EUR -2,89 EUR -3,50 %

17:18:05

STU

79,93 EUR -2,29 EUR -2,79 %

17:08:58

GVIE

Sanofi jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.99,37 Mrd. EUR

KGV12,92

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

21.05.23GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

17.05.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – April 2023

12.05.23GlobeNewswirePress Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

04.05.23GlobeNewswireSanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS

27.04.23GlobeNewswirePress Release: Sanofi completes acquisition of Provention Bio, Inc.

27.04.23GlobeNewswirePress Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

26.04.23GlobeNewswirePress Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

19.04.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2023

11.04.23GlobeNewswirePress Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

10.04.23GlobeNewswirePress Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

04.04.23PR NewswireSanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines

04.04.23GlobeNewswirePress Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

30.03.23GlobeNewswirePress Release: Availability of the Q1 2023 Memorandum for modelling purposes

23.03.23GlobeNewswirePress Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

21.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

18.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

16.03.23GlobeNewswirePress Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

14.03.23GlobeNewswireInformation concerning the total number of voting rights and shares – February 2023

13.03.23GlobeNewswirePress Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

07.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

02.03.23GlobeNewswirePress Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

24.02.23GlobeNewswireALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

24.02.23GlobeNewswirePress release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

23.02.23GlobeNewswirePress Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

15.02.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – January 2023

13.02.23GlobeNewswirePress Release: Sanofi announces change in R&D leadership

16.06.20ReutersSanofi to invest 610 millions euros at two French vaccines sites

11.06.20ReutersHealthcare group Sanofi upbeat on Dupixent opportunities

03.06.20ReutersSanofi to run consultations over restart of hydroxychloroquine trials

29.05.20ReutersExclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials

29.05.20ReutersExclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials amid safety concerns

27.05.20ReutersDrugmaker Sanofi to raise over $11 billion via sale of Regeneron shares

26.05.20ReutersSanofi shares down despite $13 billion Regeneron payday

25.05.20ReutersUPDATE 1-Regeneron to buy back $5 billion stake held by Sanofi

25.05.20ReutersU.S.' Regeneron to buy back $5 billion stake held by Sanofi

25.05.20ReutersU.S.' Regeneron to buy back $5 bln stake held by Sanofi

25.05.20ReutersSanofi to sell stake in Regeneron

15.05.20ReutersSanofi says COVID-19 vaccine will be available worldwide simultaneously

14.05.20ReutersFrance's Macron to meet Sanofi chief on May 19 - Elysee

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.